Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHN1227


Prevention of Death from Adenocarcinoma of the Lung by Low Dose Aspirin

Principal Investigator(s)

Leora Horn


  • Protocol No. VICCTHN1227
  • Open Date: 10/02/2012
  • Staging: Pilot
  • Age Group: Adults
  • Scope: Local
  • Objective: To determine whether ASA 325 mg inhibits PGE2 biosynthesis in patients with early stage NSCLC. COX catalytic activity will be determined by measuring the metabolite of PGE2, 11a-hydroxy-9,12-dioxo-2,3,4,5-tetranor-prostane-1,20 dioic acid (PGE-M) in urine pre- and post-ASA 325 mg as a surrogate of systemic PGE2 biosynthesis.
  • Disease Sites: Lung; Non Small Cell
  • Therapies: None Specified
  • Drugs: Aspirin
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01707823
  • Secondary Protocol No: Not Specified


None Provided.


Ages Eligible for Study:N/A and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


Inclusion Criteria:
• All patients with early stage (stage I-III) non-small cell lung cancer, adenocarcinoma histology
• Patients who are seen by members of the Thoracic Surgical oncology Group at Vanderbilt Ingram Cancer Center for their initial surgical consultation
Exclusion Criteria:
• Patients who have taken ASA or nonsteroidal anti-inflammatory drugs (NSAIDs) in the last two weeks or have an allergy to ASA will not be eligible for enrollment